- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | DualityBio and Genentech to Develop Next-Gen ADCs on Novel Payload Platform | ||
| Fr | FDA Approves Gilead's Bixlenvo, Once-Daily Pill for Virologically Suppressed Adults with HIV | ||
| Fr | SpyGlass Pharma Opens New Irvine Headquarters | ||
| Fr | FDA Approves Pfizer-BioNTech COVID-19 Vaccine | ||
| Fr | Evonik Invests $108M in Vancouver GMP Facility | ||
| Do | Genezen to Offer Access to 4basebio Synthetic DNA Platform for Viral Vectors | ||
| Do | Biohaven, SK Biopharmaceuticals Ink Licensing Pact for Next-Gen Epilepsy Candidate | ||
| Do | Neuland, Gland Pharma Partner on Sterile API Manufacturing | ||
| Do | Psilera Names Allyson Gage VP of Clinical Development | ||
| Do | Symbiosis Appoints Jay Chima as VP, Business Development | ||
| Do | Circio, Full Circles Partner on In Vivo Cell Therapy | ||
| Mi | Artis BioSolutions Opens Genetic Medicines Center of Excellence in Spain | ||
| Mi | Körber Releases PAS-X MES 3.4.2 for Pharma Manufacturing | ||
| Mi | Lonza Names Samanta Cimitan Chief Commercial Officer | ||
| Di | Hovione Completes Expansion of Loures, Portugal Tablet Manufacturing Center | ||
| Di | Celltrion Launches 300-mg Strength Omlyclo in Europe | ||
| Di | McKesson to Acquire Precision Medicine Group in $2.25B Deal | ||
| Di | Lundbeck, Eversana Expand AI Commercialization Partnership | ||
| Di | Hanmi Pharm, Genentech Ink $2.3B Obesity Drug Licensing Deal | ||
| Di | Cambrex High Point Site Clears FDA, PMDA, TGA Inspections | ||
| Mo | The Emmes Group Names Rama Kondru CEO | ||
| Mo | Insmed's Brinsupri Approved in Japan to Treat NCFB, Joining US and Europe | ||
| Mo | Novotech Opens Tokyo Office, Strengthening Japan Presence | ||
| Mo | Ashland Launches Permexa Sodium Caprate High-Performance Intestinal Permeation Enhancer | ||
| Mo | Barentz Appoints Matt Mitchell as Global VP, Pharmaceuticals |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.